Jubilant Pharmova Ltd Q1FY26 + FY25: Radiopharma Darling or Just Another Generic Bollywood Remake?
1. At a Glance
Jubilant Pharmova Ltd is that pharma kid in the class who tries to do everything—radiopharma, allergy immunotherapy, sterile injectables, generics, CRDMO, and even a flirtation with novel drugs. Market cap ₹17,700 Cr, P/E ~36x, debt ₹2,700 Cr, ROE stuck at 9.5%. Sales growth in five years? A sleepy 3.9%. Yet, management dreams of $570M capex and cancer drug pipelines. Basically, a Bollywood producer with a string of flops but still announcing a ₹100 Cr sci-fi trilogy.
2. Introduction
Jubilant Pharmova is not your average generic pill maker. It’s a desi pharma with a global buffet: cardiac imaging radiopharma, venom extracts for allergy, sterile injectables, APIs, and even brain-penetrant cancer molecules. It operates six plants across Canada, India, and the US, plus research hubs in Noida and Bengaluru.
But here’s the masala:
Radiopharma (44% revenue) makes it the #3 player in the US. Ruby-Fill (cardiac imaging) sells well.
Allergy immunotherapy (10%) is a niche but high-barrier business.
Sterile injectables (17%) get US govt contracts worth $150M+.
Generics (12%) are a weak link—closing the Salisbury, US plant due to losses.
CRDMO (17%) brings research dollars, including API sales to regulated markets.
Novel drugs are in Phase 1 limbo—fancy slides but zero revenue.
The geography mix screams “NRI Pharma”: 90% revenue from US & Europe, only 2% from India. In FY25, revenue was ₹7,404 Cr with PAT ₹486 Cr. Decent? Yes. Stellar? No.
So why is this company interesting? Because it’s a turnaround attempt. Debt is reducing, API business was transferred to a subsidiary, and they’re expecting a windfall from selling their 25.8% Sofie Biosciences stake for $139M. Think of it as pledging your vintage car to fund your son’s MBA.
3. Business Model – WTF Do They Even Do?
Explaining Jubilant Pharmova to your lazy investor friend is like explaining the plot of “Sacred Games” to your nani. Too many characters, everyone important, everyone confused.
Radiopharma: They make radioactive products for diagnostics. Big in US hospitals. #3 globally, #2 in US radiopharmacies.
Allergy Immunotherapy: Yes, they literally sell venom extracts for allergy therapy. Monopoly vibes in the US.
Sterile Injectables: Contract manufacturing for US govt. Think Covid vaccines, injectables, etc.
Generics: Their weakest subject. US plant shut down, India plant doing risperidone exports. Survival mode.
CRDMO: Research + APIs for regulated markets. Bread-and-butter outsourcing.
Novel Drugs: Biopharma pipeline in oncology. Currently a PowerPoint pipeline.
In short, Jubilant wants to be both Pfizer and Syngene at the same time—but right now it’s stuck between paracetamol and PowerPoint.
